<DOC>
	<DOC>NCT01624233</DOC>
	<brief_summary>This study will assess the safety and efficacy of ixekizumab in participants with moderate to severe psoriasis in Japan.</brief_summary>
	<brief_title>A Study in Japanese Participants With Moderate-to-Severe Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Men must agree to use a reliable method of birth control during the study Women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment Candidates for phototherapy and/or systemic therapy Present with chronic psoriasis based on a confirmed psoriasis diagnosis for at least 6 months prior to enrollment At least 10% Body Surface Area (BSA) of Psoriasis at screening and at enrollment for participants with plaque psoriasis Static Physician Global Assessment (sPGA) score of at least 3 and Psoriasis Area and Severity Index (PASI) score of at least 12 at screening and at enrollment for participants with plaque psoriasis History of druginduced psoriasis Concurrent or recent use of any biologic agent Received systemic psoriasis therapy [such as psoralen and ultraviolet A (PUVA) light therapy] or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to enrollment for participants with plaque psoriasis Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to enrollment and during the study Have participated in any study with interleukin17(IL17) antagonists, including ixekizumab Serious disorder or illness other than psoriasis Serious infection within the last 3 months Breastfeeding or nursing (lactating) women Clinically significant flare of psoriasis during the 12 weeks prior to enrollment for participants with plaque psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>